We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| DMG Mori AG | AQEU:GILD | Aquis Europe | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.10 | 0.23% | 43.40 | 43.40 | 43.70 | 43.40 | 43.40 | 43.40 | 100 | 16:28:05 |
From May 2019 to May 2024
Matrix Laboratories Ltd. (524794.BY) said Tuesday it has received tentative approval from the U.S. Food and Drug Administration for two generic HIV drugs.
Emtricitabine and tenofovir disoproxil fumarate tablets are the generic version of Gilead Sciences Inc.'s (GILD) truvada, the Indian drugmaker said in a statement to the Bombay Stock Exchange.
Truvada, a second-line drug to treat HIV infection, is used when patients develop resistance to initially prescribed treatments or face clinical failures.
-By Satish Sarangarajan; Dow Jones Newswires; +91 22 2288 4212; satish.sarangarajan@dowjones.com
1 Year DMG Mori Chart |
1 Month DMG Mori Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
